Efficacy and safety of later-line targeted therapies in advanced non-small cell lung cancer with EGFR exon 20 insertion mutations: a systematic review.

Front Pharmacol · 2025 · PMC12757754 · PMID 41487495

Europe PMC DOI

hedged sentence

0.2700

closest p · 5.4× alpha

0.2700

boldest claim

The sentences

did not reach statistical significanceP = 0.27not close (p > 0.1)

This trend is consistent with previous studies on amivantamab ( Park et al., 2021 ) and poziotinib ( Elamin et al., 2022 ), although the intergroup difference did not reach statistical significance (P = 0.27).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.